CN107982574B - 抗菌含钙材料 - Google Patents
抗菌含钙材料 Download PDFInfo
- Publication number
- CN107982574B CN107982574B CN201711401529.4A CN201711401529A CN107982574B CN 107982574 B CN107982574 B CN 107982574B CN 201711401529 A CN201711401529 A CN 201711401529A CN 107982574 B CN107982574 B CN 107982574B
- Authority
- CN
- China
- Prior art keywords
- lithium
- ttcp
- calcium
- paa
- dcpa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000844 anti-bacterial effect Effects 0.000 title description 57
- 239000000463 material Substances 0.000 title description 13
- 239000011575 calcium Substances 0.000 title description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title description 10
- 229910052791 calcium Inorganic materials 0.000 title description 10
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 81
- 239000000203 mixture Substances 0.000 claims abstract description 66
- 238000009472 formulation Methods 0.000 claims abstract description 46
- 239000004599 antimicrobial Substances 0.000 claims abstract description 29
- 150000002642 lithium compounds Chemical class 0.000 claims abstract description 23
- 229940043430 calcium compound Drugs 0.000 claims abstract description 13
- 150000001674 calcium compounds Chemical class 0.000 claims abstract description 13
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical group [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 claims description 185
- 229920002125 Sokalan® Polymers 0.000 claims description 155
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 122
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical group O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 claims description 100
- 239000000843 powder Substances 0.000 claims description 82
- 239000007788 liquid Substances 0.000 claims description 50
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 46
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 32
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 32
- 229910001386 lithium phosphate Inorganic materials 0.000 claims description 24
- 239000001506 calcium phosphate Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- -1 lithium halide Chemical class 0.000 claims description 19
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 17
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 16
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 15
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 15
- 229910052744 lithium Inorganic materials 0.000 claims description 15
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 15
- FUJCRWPEOMXPAD-UHFFFAOYSA-N lithium oxide Chemical compound [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 claims description 15
- 239000011148 porous material Substances 0.000 claims description 15
- TWQULNDIKKJZPH-UHFFFAOYSA-K trilithium;phosphate Chemical compound [Li+].[Li+].[Li+].[O-]P([O-])([O-])=O TWQULNDIKKJZPH-UHFFFAOYSA-K 0.000 claims description 15
- 239000001103 potassium chloride Substances 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 12
- 235000011010 calcium phosphates Nutrition 0.000 claims description 12
- 229940095672 calcium sulfate Drugs 0.000 claims description 12
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 claims description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- IIPYXGDZVMZOAP-UHFFFAOYSA-N lithium nitrate Chemical compound [Li+].[O-][N+]([O-])=O IIPYXGDZVMZOAP-UHFFFAOYSA-N 0.000 claims description 6
- 229910001947 lithium oxide Inorganic materials 0.000 claims description 6
- HGPXWXLYXNVULB-UHFFFAOYSA-M lithium stearate Chemical compound [Li+].CCCCCCCCCCCCCCCCCC([O-])=O HGPXWXLYXNVULB-UHFFFAOYSA-M 0.000 claims description 6
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
- 229910000148 ammonium phosphate Inorganic materials 0.000 claims description 4
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 4
- 239000000920 calcium hydroxide Substances 0.000 claims description 4
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 4
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000292 calcium oxide Substances 0.000 claims description 4
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 4
- KMQAPZBMEMMKSS-UHFFFAOYSA-K calcium;magnesium;phosphate Chemical compound [Mg+2].[Ca+2].[O-]P([O-])([O-])=O KMQAPZBMEMMKSS-UHFFFAOYSA-K 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 claims description 4
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 4
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 4
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 4
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229910015667 MoO4 Inorganic materials 0.000 claims description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 3
- 239000001354 calcium citrate Substances 0.000 claims description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 3
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 3
- PSHMSSXLYVAENJ-UHFFFAOYSA-N dilithium;[oxido(oxoboranyloxy)boranyl]oxy-oxoboranyloxyborinate Chemical compound [Li+].[Li+].O=BOB([O-])OB([O-])OB=O PSHMSSXLYVAENJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 claims description 3
- NMHMDUCCVHOJQI-UHFFFAOYSA-N lithium molybdate Chemical compound [Li+].[Li+].[O-][Mo]([O-])(=O)=O NMHMDUCCVHOJQI-UHFFFAOYSA-N 0.000 claims description 3
- IDNHOWMYUQKKTI-UHFFFAOYSA-M lithium nitrite Chemical compound [Li+].[O-]N=O IDNHOWMYUQKKTI-UHFFFAOYSA-M 0.000 claims description 3
- WNCZOFYWLAPNSS-UHFFFAOYSA-M lithium;3-carboxy-3,5-dihydroxy-5-oxopentanoate Chemical compound [Li+].OC(=O)CC(O)(C(O)=O)CC([O-])=O WNCZOFYWLAPNSS-UHFFFAOYSA-M 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 235000016337 monopotassium tartrate Nutrition 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 239000004224 potassium gluconate Substances 0.000 claims description 3
- 229960003189 potassium gluconate Drugs 0.000 claims description 3
- 235000013926 potassium gluconate Nutrition 0.000 claims description 3
- 229940086065 potassium hydrogentartrate Drugs 0.000 claims description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 3
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 claims description 3
- 229940074439 potassium sodium tartrate Drugs 0.000 claims description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 3
- 235000011151 potassium sulphates Nutrition 0.000 claims description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000011697 sodium iodate Substances 0.000 claims description 3
- 239000001540 sodium lactate Substances 0.000 claims description 3
- 235000011088 sodium lactate Nutrition 0.000 claims description 3
- 229940005581 sodium lactate Drugs 0.000 claims description 3
- 235000011006 sodium potassium tartrate Nutrition 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical group [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 claims description 2
- 229940095564 anhydrous calcium sulfate Drugs 0.000 claims description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 2
- 229910000388 diammonium phosphate Inorganic materials 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229910000150 monocalcium phosphate Inorganic materials 0.000 claims description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims 4
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000007943 implant Substances 0.000 abstract description 23
- 238000002360 preparation method Methods 0.000 abstract description 14
- 210000000988 bone and bone Anatomy 0.000 abstract description 9
- 239000007787 solid Substances 0.000 abstract description 8
- 235000019700 dicalcium phosphate Nutrition 0.000 description 117
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 115
- 239000000243 solution Substances 0.000 description 77
- 239000004568 cement Substances 0.000 description 69
- 150000001875 compounds Chemical class 0.000 description 41
- 238000007654 immersion Methods 0.000 description 34
- 238000002156 mixing Methods 0.000 description 33
- 239000012981 Hank's balanced salt solution Substances 0.000 description 29
- 150000003839 salts Chemical class 0.000 description 28
- 238000012360 testing method Methods 0.000 description 26
- 239000011812 mixed powder Substances 0.000 description 25
- 238000000034 method Methods 0.000 description 20
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 16
- 230000003833 cell viability Effects 0.000 description 15
- 239000002245 particle Substances 0.000 description 14
- 239000001974 tryptic soy broth Substances 0.000 description 14
- 229910019142 PO4 Inorganic materials 0.000 description 13
- 108010050327 trypticase-soy broth Proteins 0.000 description 13
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 12
- 239000013585 weight reducing agent Substances 0.000 description 12
- 238000000748 compression moulding Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000008187 granular material Substances 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 229910052783 alkali metal Inorganic materials 0.000 description 9
- XUCJHNOBJLKZNU-UHFFFAOYSA-M dilithium;hydroxide Chemical compound [Li+].[Li+].[OH-] XUCJHNOBJLKZNU-UHFFFAOYSA-M 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 9
- 239000010452 phosphate Substances 0.000 description 9
- PQXKHYXIUOZZFA-UHFFFAOYSA-M lithium fluoride Chemical compound [Li+].[F-] PQXKHYXIUOZZFA-UHFFFAOYSA-M 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000006150 trypticase soy agar Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 5
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000007493 shaping process Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 4
- 238000001139 pH measurement Methods 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001427 coherent effect Effects 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960000707 tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000037408 Device failure Diseases 0.000 description 1
- 241000557622 Garrulus glandarius Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910052925 anhydrite Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- 229960004489 cefonicid Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/12—Materials or treatment for tissue regeneration for dental implants or prostheses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Materials Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
1d | 2d | 3d | 5d | 7d | |
3%PAA | 11.4 | 10.3 | 8.5 | 6 | 6 |
5%PAA | 11.5 | 11.4 | 11.3 | 6 | 6 |
10%PAA | 12.6 | 12.5 | 11.7 | 6.7 | 6 |
1d | 2d | 3d | 4d | 5d | 6d | 7d | 8d | 9d | 10d | |
3%PAA | 11.4 | 12.2 | 12.0 | 11.6 | 11.2 | 10.7 | 10.6 | 10.5 | 10.4 | 10.3 |
5%PAA | 10.7 | 11.9 | 12.1 | 11.8 | 11.4 | 11.1 | 10.7 | 10.6 | 10.4 | 10.3 |
10%PAA | 10.5 | 11.0 | 11.5 | 11.9 | 11.5 | 11.1 | 10.7 | 10.6 | 10.4 | 10.3 |
1d | 2d | 3d | 5d | 7d | 10d | |
3%PAA | 11.4 | 14.9 | 17 | 23.8 | 24.4 | 27.4 |
5%PAA | 12.4 | 20.9 | 24.9 | 28.5 | 30.1 | 37.9 |
10%PAA | 15.3 | 22.5 | 28.9 | 38.6 | 39.6 | 42.8 |
1d | 2d | 3d | 5d | 7d | 10d | |
3%PAA | 39.8 | 41.2 | 42.0 | 43.2 | 43.4 | 50.0 |
5%PAA | 38.2 | 40.9 | 42.7 | 44.6 | 48.6 | 51.8 |
10%PAA | 40.8 | 42.9 | 45.1 | 44.8 | 57.4 | 75.0 |
1d | 2d | 3d | 5d | 7d | |
3%PAA | 12.5 | 9.9 | 9.8 | 6 | 6 |
5%PAA | 12.7 | 10.6 | 10.9 | 7.3 | 6 |
10%PAA | 11.9 | 11.5 | 10.6 | 8.8 | 6.9 |
1d | 2d | 3d | 4d | 5d | 6d | 7d | 8d | 9d | 10d | |
3%PAA | 10.5 | 10.5 | 10.8 | 10.8 | 10.6 | 10.5 | 10.4 | - | - | - |
5%PAA | 10.5 | 10.7 | 10.7 | 10.7 | 10.8 | 10.6 | 10.4 | - | - | - |
10%PAA | 10.5 | 10.8 | 10.8 | 10.8 | 10.7 | 10.7 | 10.7 | - | - | - |
1d | 2d | 3d | 5d | 7d | 10d | |
3%PAA | 7.6 | 14 | 25.1 | 27.2 | 27.4 | - |
5%PAA | 8.5 | 14.3 | 26.1 | 32.1 | 33.9 | - |
10%PAA | 8.6 | 20.9 | 26.6 | 32.3 | 41.0 | - |
1d | 2d | 3d | 5d | 7d | 10d | |
3%PAA | 26.0 | 43.1 | 42.9 | - | - | 48.1 |
5%PAA | 25.7 | 44.0 | 43.9 | - | - | 70.6 |
10%PAA | 27.3 | 44.9 | 51.2 | - | - | 80.3 |
1d | 2d | 3d | 5d | 7d | |
3%PAA | 11.7 | 8.0 | 6 | 6 | 6 |
5%PAA | 12.7 | 8.0 | 6 | 6 | 6 |
10%PAA | 13.0 | 10.0 | 11.0 | 6 | 6 |
1d | 2d | 3d | 4d | 5d | 6d | 7d | 8d | 9d | 10d | |
3%PAA | 11.9 | 12.1 | 11.5 | 11.0 | 10.8 | 10.5 | 10.5 | - | - | - |
5%PAA | 10.9 | 12.2 | 11.8 | 11.1 | 10.9 | 10.6 | 10.5 | - | - | - |
10%PAA | 10.2 | 11.5 | 12.1 | 11.6 | 11.1 | 10.7 | 10.6 | - | - | - |
1d | 2d | 3d | 5d | 7d | 10d | |
3%PAA | 20.7 | 24.6 | 25.0 | 31.8 | 33.8 | |
5%PAA | 18.6 | 25.9 | 30.2 | 33.3 | 37.4 | |
10%PAA | 19.1 | 27.4 | 32.4 | 33.3 | 40.0 |
1d | 2d | 3d | 5d | 7d | 10d | |
3%PAA | 38.1 | 39.7 | 40.2 | 40.7 | 50.8 | 51.9 |
5%PAA | 38.5 | 40.0 | 42.2 | 42.9 | 54.7 | 60.9 |
10%PAA | 42.2 | 42.6 | 43.1 | 43.7 | 55.1 | 76.7 |
1d | 2d | 3d | 5d | 7d | |
3%PAA | 11.0 | 8.0 | 6.3 | 6 | 6 |
5%PAA | 10.7 | 10.0 | 6.7 | 6 | 6 |
10%PAA | 11.0 | 10.0 | 10.0 | 9.0 | 7.5 |
1d | 2d | 3d | 4d | 5d | 6d | 7d | 8d | 9d | 10d | |
3%PAA | 10.1 | 11.1 | 11.0 | 10.8 | 10.6 | 10.5 | 10.4 | 10.3 | 10.2 | 10.1 |
5%PAA | 10.1 | 11.1 | 11.2 | 10.8 | 10.7 | 10.5 | 10.5 | 10.3 | 10.2 | 10.1 |
10%PAA | 10.2 | 10.7 | 10.6 | 10.7 | 10.9 | 10.7 | 10.7 | 10.6 | 10.3 | 10.2 |
1d | 2d | 3d | 5d | 7d | 10d | |
3%PAA | 19.5 | 25.8 | 29.5 | 35.3 | 41.2 | 43.2 |
5%PAA | 17.3 | 22.8 | 28.3 | 31.7 | 42.9 | 45.6 |
10%PAA | 15.2 | 23.3 | 28.7 | 40.2 | 48.3 | 49.5 |
1d | 2d | 3d | 5d | 7d | 10d | |
3%PAA | 49.9 | 50.2 | 50.5 | 51.0 | 54.2 | 54.2 |
5%PAA | 55.6 | 55.5 | 55.6 | 58.6 | 59.3 | 60.3 |
10%PAA | 64.6 | 65.9 | 64.4 | 65.1 | 68.3 | 86.1 |
Li盐 | Li盐量/TSB(克/毫升) | 抗微生物活性(24小时)(%) |
Li<sub>3</sub>PO<sub>4</sub> | 0.06 | 98.9 |
Li<sub>3</sub>PO<sub>4</sub> | 0.08 | 98.9 |
Li<sub>3</sub>PO<sub>4</sub> | 0.10 | 97.4 |
Li<sub>3</sub>PO<sub>4</sub> | 0.12 | 98.8 |
Li<sub>3</sub>PO<sub>4</sub> | 0.14 | 99.8 |
Li<sub>2</sub>CO<sub>3</sub> | 0.06 | 100 |
Li<sub>2</sub>CO<sub>3</sub> | 0.08 | 100 |
Li<sub>2</sub>CO<sub>3</sub> | 0.10 | 100 |
Li<sub>2</sub>CO<sub>3</sub> | 0.12 | 100 |
Li<sub>2</sub>CO<sub>3</sub> | 0.14 | 100 |
样品 | 抗微生物活性(24小时)(%) |
Li<sub>3</sub>PO<sub>4</sub>:65/35=25:75以重量计 | 81 |
Li<sub>3</sub>PO<sub>4</sub>:65/35=50:50以重量计 | 100 |
Li<sub>2</sub>CO<sub>3</sub>:65/35=25:75以重量计 | 100 |
Li<sub>2</sub>CO<sub>3</sub>:65/35=50:50以重量计 | 100 |
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711401529.4A CN107982574B (zh) | 2012-05-07 | 2013-05-06 | 抗菌含钙材料 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261643500P | 2012-05-07 | 2012-05-07 | |
CN201711401529.4A CN107982574B (zh) | 2012-05-07 | 2013-05-06 | 抗菌含钙材料 |
CN201380023551.3A CN104302300B (zh) | 2012-05-07 | 2013-05-06 | 抗菌含钙材料 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380023551.3A Division CN104302300B (zh) | 2012-05-07 | 2013-05-06 | 抗菌含钙材料 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107982574A CN107982574A (zh) | 2018-05-04 |
CN107982574B true CN107982574B (zh) | 2021-01-01 |
Family
ID=49512698
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380023551.3A Active CN104302300B (zh) | 2012-05-07 | 2013-05-06 | 抗菌含钙材料 |
CN201711401529.4A Active CN107982574B (zh) | 2012-05-07 | 2013-05-06 | 抗菌含钙材料 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380023551.3A Active CN104302300B (zh) | 2012-05-07 | 2013-05-06 | 抗菌含钙材料 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10207023B2 (zh) |
EP (1) | EP2846811B1 (zh) |
JP (1) | JP6174684B2 (zh) |
KR (3) | KR102214257B1 (zh) |
CN (2) | CN104302300B (zh) |
TW (1) | TWI630003B (zh) |
WO (1) | WO2013169633A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI651103B (zh) | 2013-12-13 | 2019-02-21 | 萊特醫技股份有限公司 | 多相骨移植替代材料 |
CN110558311A (zh) * | 2019-09-17 | 2019-12-13 | 海南医学院第一附属医院 | 一种创战伤中保存离体骨的医用材料及其制备方法 |
KR102284280B1 (ko) * | 2019-12-13 | 2021-08-02 | 가톨릭대학교 산학협력단 | 착색방지기능을 가지는 코팅 조성물 및 이를 이용한 임시 치관 |
CN117339026B (zh) * | 2023-11-09 | 2024-05-14 | 广州医科大学附属口腔医院(广州医科大学羊城医院) | 用于植入人体牙槽骨中的可吸收支架的制备及应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000313817A (ja) * | 1999-04-30 | 2000-11-14 | Ishizuka Glass Co Ltd | 樹脂添加剤 |
CN1475279A (zh) * | 2002-08-13 | 2004-02-18 | 中国科学院福建物质结构研究所 | 一种羟基磷灰石骨水泥人工骨的制备方法 |
CN1937989A (zh) * | 2004-05-29 | 2007-03-28 | 肖特股份公司 | 作为牙科材料的抗菌添加物的玻璃组分 |
JP2007084450A (ja) * | 2005-09-20 | 2007-04-05 | Asahi Fiber Glass Co Ltd | 抗菌剤、それを含む樹脂組成物及び成形材料 |
CN101686861A (zh) * | 2007-07-09 | 2010-03-31 | 艾斯特勒科技公司 | 包含锂离子的骨组织植入物 |
CN102014976A (zh) * | 2008-02-29 | 2011-04-13 | 史密夫和内修有限公司 | 涂层和涂覆方法 |
CN102452831A (zh) * | 2010-10-19 | 2012-05-16 | 成功大学 | 骨水泥制剂以及由该骨水泥制剂制备的生物可再吸收的硬化骨水泥复合材料 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6117409A (ja) * | 1984-07-02 | 1986-01-25 | Meishin Toryo Kk | 非晶質リン酸カルシウムの製法およびこれを主成分とする生体適応性組成物 |
US5705273A (en) * | 1995-03-08 | 1998-01-06 | The Ohio State University | Method for strengthening dental restorative materials |
US6071528A (en) * | 1997-02-19 | 2000-06-06 | Ultradent Products, Inc. | Adhesive antimicrobial and/or reparative dentin stimulating dental compositions and methods for forming and using such compositions |
SE0201052D0 (sv) * | 2002-04-04 | 2002-04-04 | Cerbio Tech Ab | Biocompatible cement compositions and method of manufacturing |
US6930144B2 (en) * | 2003-06-24 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Cement system including a binder for use in freeform fabrication |
WO2008102214A2 (en) * | 2007-02-22 | 2008-08-28 | Ghassemian Pour Bavandi, Madjid | Endodontic filling material |
US8815973B2 (en) * | 2007-08-28 | 2014-08-26 | Pioneer Surgical Technology, Inc. | Cement products and methods of making and using the same |
US8052787B2 (en) * | 2007-09-28 | 2011-11-08 | National Taiwan University | Bio-material and method of preparation thereof |
KR100957543B1 (ko) * | 2008-01-28 | 2010-05-11 | 연세대학교 산학협력단 | 비정질 칼슘 포스페이트를 함유하는 골대체용 조성물 |
KR20110000636A (ko) * | 2008-02-20 | 2011-01-04 | 오거마 바이오머티리얼스 리미티드 | 골 이식재 및 이의 용도 |
EP2254610A4 (en) * | 2008-02-22 | 2013-07-31 | Dermal Technologies Llc | COMPOSITIONS FOR TISSUE REINFORCEMENT |
WO2011040851A1 (en) * | 2009-10-02 | 2011-04-07 | Doxa Ab | Calcium aluminate based paste for stabilizing dental implants and restoring tissue attachment after surgery and methods therefor |
US8778378B2 (en) * | 2009-12-21 | 2014-07-15 | Orthovita, Inc. | Bioactive antibacterial bone graft materials |
EP2611438B1 (en) * | 2010-08-30 | 2020-04-01 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
CN103228245A (zh) * | 2010-10-06 | 2013-07-31 | 可乐丽则武齿科株式会社 | 牙本质小管封闭剂及其制造方法 |
-
2013
- 2013-05-06 US US13/887,416 patent/US10207023B2/en active Active
- 2013-05-06 KR KR1020207015455A patent/KR102214257B1/ko active IP Right Grant
- 2013-05-06 JP JP2015511567A patent/JP6174684B2/ja active Active
- 2013-05-06 CN CN201380023551.3A patent/CN104302300B/zh active Active
- 2013-05-06 KR KR1020147031072A patent/KR20150004826A/ko not_active Application Discontinuation
- 2013-05-06 WO PCT/US2013/039661 patent/WO2013169633A1/en active Application Filing
- 2013-05-06 CN CN201711401529.4A patent/CN107982574B/zh active Active
- 2013-05-06 KR KR1020207012751A patent/KR20200050477A/ko not_active Application Discontinuation
- 2013-05-06 TW TW102116122A patent/TWI630003B/zh active
- 2013-05-06 EP EP13787118.2A patent/EP2846811B1/en active Active
-
2018
- 2018-12-18 US US16/223,773 patent/US20190117826A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000313817A (ja) * | 1999-04-30 | 2000-11-14 | Ishizuka Glass Co Ltd | 樹脂添加剤 |
CN1475279A (zh) * | 2002-08-13 | 2004-02-18 | 中国科学院福建物质结构研究所 | 一种羟基磷灰石骨水泥人工骨的制备方法 |
CN1937989A (zh) * | 2004-05-29 | 2007-03-28 | 肖特股份公司 | 作为牙科材料的抗菌添加物的玻璃组分 |
JP2007084450A (ja) * | 2005-09-20 | 2007-04-05 | Asahi Fiber Glass Co Ltd | 抗菌剤、それを含む樹脂組成物及び成形材料 |
CN101686861A (zh) * | 2007-07-09 | 2010-03-31 | 艾斯特勒科技公司 | 包含锂离子的骨组织植入物 |
CN102014976A (zh) * | 2008-02-29 | 2011-04-13 | 史密夫和内修有限公司 | 涂层和涂覆方法 |
CN102452831A (zh) * | 2010-10-19 | 2012-05-16 | 成功大学 | 骨水泥制剂以及由该骨水泥制剂制备的生物可再吸收的硬化骨水泥复合材料 |
Also Published As
Publication number | Publication date |
---|---|
EP2846811B1 (en) | 2018-03-14 |
US20130295193A1 (en) | 2013-11-07 |
KR102214257B1 (ko) | 2021-02-09 |
KR20200050477A (ko) | 2020-05-11 |
EP2846811A1 (en) | 2015-03-18 |
US10207023B2 (en) | 2019-02-19 |
US20190117826A1 (en) | 2019-04-25 |
KR20150004826A (ko) | 2015-01-13 |
CN104302300A (zh) | 2015-01-21 |
JP6174684B2 (ja) | 2017-08-02 |
EP2846811A4 (en) | 2015-05-06 |
WO2013169633A1 (en) | 2013-11-14 |
CN107982574A (zh) | 2018-05-04 |
KR20200065099A (ko) | 2020-06-08 |
CN104302300B (zh) | 2018-09-14 |
TW201345570A (zh) | 2013-11-16 |
JP2015520148A (ja) | 2015-07-16 |
TWI630003B (zh) | 2018-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mouriño et al. | Preparation and characterization of gallium releasing 3‐D alginate coated 45S5 Bioglass® based scaffolds for bone tissue engineering | |
US20190117826A1 (en) | Antibacterial calcium-based materials | |
US8784551B2 (en) | Bone cement formula and bioresorbable hardened bone cement composites prepared with the same | |
Liu et al. | Melt-compounded polylactic acid composite hybrids with hydroxyapatite nanorods and silver nanoparticles: Biodegradation, antibacterial ability, bioactivity and cytotoxicity | |
US20180093009A1 (en) | Dimensionally Stable Molded Bone Replacement Element with Residual Hydraulic Activity | |
RU2376019C2 (ru) | Пористые композиционные материалы на основе хитозана для заполнения костных дефектов | |
Keshavarz et al. | On the role of alginate coating on the mechanical and biological properties of 58S bioactive glass scaffolds | |
Govindan et al. | Drug loaded phosphate glass/hydroxyapatite nanocomposite for orthopedic applications | |
Czechowska et al. | The importance of chitosan and nano-TiHA in cement-type composites on the basis of calcium sulfate | |
KR101140650B1 (ko) | 고주입성 칼슘계 골시멘트 조성물 | |
Liu et al. | Study on injectable silver-incorporated calcium phosphate composite with enhanced antibacterial and biomechanical properties for fighting bone cement-associated infections | |
TWI388348B (zh) | 含有聚合物或寡聚物之矽酸鈣系骨水泥及其製法 | |
KR101654600B1 (ko) | 주입형 자가-경화 인회석 시멘트를 포함하는 조성물 | |
Suwanprateeb et al. | Preparation and characterizations of antibiotic impregnated microporous nano-hydroxyapatite for osteomyelitis treatment | |
Komlev et al. | Investigation of physicochemical and biological properties of composite matrices in a alginate–calcium phosphate system intended for use in prototyping technologies during replacement of bone defects | |
Dong et al. | Silk fibroin hydrogels induced and reinforced by acidic calcium phosphate–A simple way of producing bioactive and drug-loadable composites for biomedical applications | |
EP2450064B1 (en) | Bone Cement Formula and Bioresorbable Hardened Bone Cement Composites Prepared with the Same | |
CN112717206A (zh) | 一种介孔硅酸钙镁/磷酸铵镁复合材料及用该复合材料制备骨水泥和骨架的方法 | |
Otsuka | Development of skeletal drug delivery system based on apatite/collagen composite cement | |
JP2004049589A (ja) | 不定形骨補填材 | |
Czechowska et al. | Chemically bonded, calcium phosphate based bioceramics with addition of calcium sulphate | |
PL235083B1 (pl) | Sposób otrzymywania implantu metalicznego pokrytego powłoką oraz implant metaliczny pokryty powłoką | |
Linde et al. | Evaluierung von Knochenersatzmaterialien im" Jenaer Schädelmo-dell" mit microCT and Hartgewebe-Histologie | |
WO2012054010A1 (en) | Bone cement formula and bioresorbable hardened bone cement composites prepared with the same | |
TW201217296A (en) | Bone cement formula and bioresorbable hardened bone cement composites prepared with the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240529 Address after: Two China Taiwan Kaohsiung City Road No. 63 1F District bamboo Branch Road Branch Patentee after: JOY MEDICAL DEVICES Corp. Country or region after: TaiWan, China Address before: 911 Tower Road, Yunnecka, Illinois 60093, USA Patentee before: Chen Jinhui Country or region before: U.S.A. Patentee before: Zhu Jianping Patentee before: Chen Changgeng Country or region before: TaiWan, China Patentee before: Yang Bingchen |